-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2025-10-24
GenSci Invites You to Meet Us at CPHI FRANKFURT 2025Learn More
-
2025-10-24
GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMSLearn More
-
2025-10-13
GenSci Advances Women's Health with the Approval of Two Key ProductsLearn More
-
2025-10-09
From Long-acting Growth Hormone to Medical Devices: GenPEG Advances its High-purity ExpertiseLearn More
-
2025-07-14
First Prescription for Firsekibart Issued in China for GALearn More
-
2025-06-18
Gensci Showcases Women's Health and Immunology Innovations at BIO 2025Learn More